Where does Novavax, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novavax, Inc. ranks #8,654 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novavax, Inc. hold?

Novavax, Inc. holds 37 US utility patents granted between 2015 and 2024, spanning 6 technology areas.

What is Novavax, Inc.'s Innovation Score?

Novavax, Inc. has an Innovation Score of 39.3 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novavax, Inc. focus on?

Novavax, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 37 patents, ranking #502 of 6,058 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Novavax, Inc.'s patent grant rate increasing or decreasing?

Novavax, Inc.'s recent grant velocity is -24% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Novavax, Inc.'s patents?

Novavax, Inc.'s patents average 19.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novavax, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Novavax, Inc.

USPTO PatentsView assignee record - 37 granted patents across 6 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novavax ranks #8,654 of 49,997 tracked US assignees by granted-patent volume, with 37 patents across 6 technology areas.

#8,654
of 49,997 US assignees by volume: Top 38%
by Innovation Score (39.3/100): 19.0
avg claims per patent: -24%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8654 · US Corporation #8,654 · 37 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 37 grants
UPPER-Q #8,654/49,997
PHOTO-FINISH Net Entertainment…
CPC-NARROW A61P · 6 areas
INNOV-THIN 39.3/100
CLAIMS-RICH 19.0 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -24% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Net Entertainment Malta Services, Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novavax’s 39.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.6 pts (32%) Velocity 6.7 pts (17%) Breadth 8.7 pts (22%) Claim depth 11.4 pts (29%)

Qualcomm Incorporated · highest

85
Andreas Hettich & KG · near

39
Echogen Power Systems · near

39
Japan OIL GAS AND… · near

39
Novavax · this assignee

39
Somos · near

39
3D Lighting… · lowest

7

What this shows Novavax's Innovation Score is 39.3/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novavax?

Each dot is one of Novavax’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novavax’s own 19.0 claims/patent is ABOVE the 9.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Novavax vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novavax's grants concentrate

Novavax, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (6 grants) versus a trough of 1 in 2023. By volume, Novavax sits between Nippon Thermostat Co., Ltd. and Once Innovations, Inc..

Novavax's three-year grant acceleration

Novavax, Inc. shows 9 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nippon Thermostat

37
Net Entertainment…

37
Neurowave Systems

37
Novan

37
OCI

37
Optex

37
Orthohelix Surgic…

37
Once Innovations

37
Novavax ◀

37

What this shows Novavax holds 37 patents at rank #8,653, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novavax

By rank, the assignees closest to #8,653 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Novavax's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novavax, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Novavax ranks #502 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Somos, Inc. 39 Andreas Hettich GmbH & Co. KG 39 Echogen Power Systems, LLC 39 Japan OIL, GAS AND Metals National Corporation 39

Novavax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 38% higher than 62% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Novavax, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	13.5%
2016	3	8.1%
2017	6	16.2%
2018	5	13.5%
2019	2	5.4%
2020	4	10.8%
2021	3	8.1%
2022	5	13.5%
2023	1	2.7%
2024	3	8.1%

Which technologies does Novavax, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 37

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 37

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 35

C07K - Peptides 28

C12Y - Enzymes 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novavax, Inc.'s patent record in context - here's where to go next.

Novavax, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #8,654 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novavax, Inc. against Nippon Thermostat Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.